FEBRUARY 19 – 24, 2017: Molecular Med Tri-Con
Molecular Med Tri-Con
February 19-24, 2017 • San Francisco, CA
Why is the Tri-Conference the Premier Event on Molecular Medicine & Diagnostics?
If you are working in diagnostics and drug discovery, this is the must attend event of the year.
Attracting over 3,500 drug discovery and development professionals from over 40 countries in 2016, the Tri-Conference has grown into a diverse event, focusing on Molecular Medicine, specifically on Discovery, Genomics, Diagnostics and Information Technology.
The Informatics Channel gathers leading experts in big data science, drug discovery informatics, bioinformatics, and IT to explore cutting edge ways to manage, analyze, model, and integrate data that is clinically actionable and transforms our understanding of translational research and precision medicine. http://www.triconference.com/informatics/
Molecular technologies are essential to accurately understand and effectively diagnose disease and guide therapy. The Diagnostics Channel will bring together industry leaders to discuss best practices in the creation and implementation of tools to enable precision medicine. http://www.triconference.com/Diagnostics/
As researchers continue to unveil the importance and role of the human genome in the diagnosis and treatment of disease, it will be critical to maintain a multi-faceted approach. Covering everything from sample preparation and molecular technologies to data analysis and clinical implementation, the Genomics Channel will showcase the techniques and emerging trends in precision medicine and beyond. http://www.triconference.com/genomics/
The heterogeneity and complexity of malignant tumors has changed the way we think about the initiation, progression, diagnosis, and management of cancer. The Cancer Channel will explore the emerging molecular markers, improved preclinical models, genomic-based, and immunotherapies that are enabling precision oncology. http://www.triconference.com/cancer/
- New Frontiers in CRISPR-Based Gene Editing
- Circulating Cell-Free DNA
- Point-of-Care Diagnostics
- Biomarkers for Cancer Immunotherapy
- Genomic Knowledge Bases, Annotation and Interpretation
- Microbiome-Based Precision Medicine – New
- Commercialization of Molecular Diagnostics